Brilliant: A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
Study Details
Study Description
Brief Summary
The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
This is a non-interventional, ambispective (retrospective + prospective) study of Chinese participants with ALK-positive locally advanced or metastatic NSCLC receiving brigatinib as their first line of treatment from September 1, 2022 and December 31, 2023.This study will evaluate the time-to-treatment discontinuation and other efficacy outcomes of brigatinib in participants with NSCLC in real-world settings.
This study will enroll approximately 200 participants in the following cohort:
• Brigatinib 90 mg/180mg
This study is an ambispective study that will have prospective data collection if the study is approved before December 2023 or it will have retrospective data collection if the study is approved after December 2023.
This multi-center trial will be conducted in China. Participants will be followed up for safety from signing informed consent until 36 months after the last dose of treatment or until death of the last participant. The overall time for data collection is approximately 52 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Brigatinib 90 mg/180mg Participants with ALK positive locally advanced or metastatic NSCLC will be observed ambispectively (retrospective plus prospective) after receiving recommended dose of brigatinib, 90 mg orally once daily for first 7 days followed by 180 mg once daily for up to 36 months as their first line of treatment as part of routine medical care up to approximately 16 months. Data will be collected every 3 months after their first dose until the 36 month or participant death, loss to follow-up, or withdrawal from the study for any reason in the real-world setting from September 1, 2022 and December 31, 2026. |
Drug: Brigatinib
Brigatinib Tablets
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Real-World Time-to-Treatment Discontinuation (rwTDD) [Up to 52 months]
rwTTD is defined as the time from initiation of brigatinib to discontinuation of treatment for any reason, including disease progression, death, serious adverse events, or participant preference.
Secondary Outcome Measures
- Real-World Progression-Free Survival (rwPFS) [Up to 52 months]
rwPFS is defined as the time from initiation of brigatinib to disease progression or death from any cause, or the time of the last confirmed survival.
- Real-World Progression-Free Survival at Years 1, 2 and 3 [Up to 52 months]
rwPFS at years 1,2 and 3 is defined as the probability of progression-free survival/ survival over one year; the probability of progression-free survival/survival over two years; the probability of progression-free survival/survival over three years.
- Real-World Overall Survival (rwOS) at Years 1, 2 and 3 [Up to 52 months]
rwOS is defined as the time from initiation of brigatinib to death from any cause, or the time of the last confirmed survival.
- Real-World Objective Response Rate (rwORR) [Up to 52 months]
rwORR is defined as the percentage of participants who are confirmed to achieved complete response (CR) or partial response (PR) after receiving brigatinib.
- Real-World Duration of Response (rwDOR) [Up to 52 months]
rwDOR is defined as the time from the first assessment of CR or PR after receiving first line treatment with brigatinib to progression or death.
Eligibility Criteria
Criteria
Inclusion Criteria
-
Age ≥ 18 years.
-
Participant with histologically/cytologically confirmed locally advanced or metastatic NSCLC.
-
Participants with ALK gene rearrangement confirmed by local hospital medical records.
-
During the period from September 1, 2022 to December 31, 2023, participants who received brigatinib as first line treatment confirmed by medical records.
-
Participants who have at least one medical record after the start of brigatinib treatment.
Exclusion Criteria
-
Participants participated in NSCLC-related interventional clinical trials after locally advanced or metastatic NSCLC diagnosis and during brigatinib treatment.
-
Previously received any other TKIs, including ALK-targeted TKIs.
-
Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.
-
Participants have been diagnosed as malignancies (excluding completely resected basal cell carcinoma, bladder carcinoma in situ, cervical carcinoma in situ) in addition to NSCLC within the past 5 years.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Oncology, Shanghai pulmonary hospital | Shanghai | Shanghai | China | 200433 |
Sponsors and Collaborators
- Takeda
Investigators
- Study Director: Study Director, Takeda
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Brigatinib-4002